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Insulin resistance is defined as an inability of target tissues to act in response to insulin, 
a crucial anabolic hormone. It is considered a prediabetic state and is often associated 
with obesity. Insulin resistance can be detected even years before the onset of type 2 
diabetes, and thus it is an important target for prevention. Type 2 diabetes is one of the 
known preventable risk factors for Alzheimer’s disease (AD), the most common type of 
memory disorder. Nevertheless, insulin resistance alone seems to be an independent risk 
factor for cognitive impairment and further development of AD. There are several 
possible pathophysiological explanations for this association.  The purpose of this 
literature review is to investigate the possible connection between insulin resistance and 
loss of brain white matter integrity as both phenomena are known to occur in Alzheimer’s 
disease.  
In this literature review, the focus is on recent findings about insulin resistance and white 
matter integrity impairment detected by a modality of magnetic resonance imaging called 
diffusion tensor imaging (DTI). For background, insulin resistance, Alzheimer’s disease 
and their connection are discussed in detail. To date, a few cross-sectional studies have 
been published that concentrate on insulin resistance and white matter integrity loss. 
These suggest that insulin resistance might have an impact on white matter integrity. 
More extensive follow-up studies are needed to establish a connection between insulin 
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Insulin is an essential anabolic hormone produced in the pancreas that regulates glucose uptake into 
the cells. Insulin resistance (IR) is a condition in which responsiveness to insulin has declined, 
meaning that insulin-mediated glucose uptake is impaired in tissues. Skeletal muscle is the most 
important tissue regarding glucose metabolism, but insulin also has effects on other tissues. In the 
liver, insulin resistance further stimulates gluconeogenesis. Compromised glucose uptake and 
upregulated gluconeogenesis together cause hyperglycemia. (Sesti, 2006; Laakso, 2015.) In adipose 
tissue insulin prevents lipolysis and release of free fatty acids into the circulation. It has been shown 
that free fatty acids further inhibit insulin signaling and promote hyperglycemia. (Gastaldelli et al., 
2010.)  
 
Inflammation (chronic low-grade inflammation) has been linked to the pathogenesis of IR as well.  
For instance, an inflammatory cytokine TNF-α (tumor necrosis factor alpha) is upregulated in adipose 
tissue and it contributes to IR (Hotamisligil et al., 1996; Verdile et al., 2015). Persistent IR burdens 
the β-cells of the pancreas and suppresses insulin production, eventually leading to insulin deficiency 
(Verdile et al., 2015). 
 
Lifestyle and environmental factors contribute greatly to the development of IR, central obesity being 
perhaps the most significant factor. However, it has become clearer that genetics have an effect on 
IR as well. (Beale, 2013.) IR naturally predisposes to type 2 diabetes (T2D), but in addition it has 
strong associations with cardiovascular diseases. IR alters the lipid profile in blood: triglyceride level 
increases whereas high-density lipoprotein (HDL) cholesterol level decreases, which are both well-
known atherosclerosis risk factors. Hypertension is often associated with IR, which may be explained 
by over-expression of renin-angiotensin-aldosterone-system. (Ormazabal et al., 2018.) The 





1.1.2 Measurements of insulin resistance 
 
Clinically, the easiest measurement method for IR is the oral glucose tolerance test (OGTT) in which 
the subject ingests 75 g of glucose dissolved in water. Fasting plasma glucose has been measured 
before glucose intake and two hours after the test glucose value is measured again – or sometimes, 
for research purpose, various times over the two-hour period. In healthy adults, glucose value peaks 
at 30-60 minutes and returns to baseline at two hours. QUICKI (Quantitative Insulin sensitivity Check 
Index) describes insulin sensitivity only using fasting blood glucose and insulin values. (Borai, 
Livingstone and Ferns, 2007.) 
 
The euglycemic hyperinsulinemic clamp is considered the golden standard of IR assessment but it is 
a rather invasive and complex test and used mostly in research. The method is based on infusing 
simultaneously both insulin and glucose into the study subject until a steady state of blood glucose is 
reached, and reliable values of exogenous insulin and glucose can be measured. (Borai, Livingstone 
and Ferns, 2007.) HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a 
mathematical model that can be used to estimate IR and β-cell function using plasma insulin and 
glucose values. It correlates well with the clamp test and is more practical to use. (Wallace, Levy and 
Matthews, 2004.)  
 
 
1.1.3 Insulin in the brain 
 
Glucose uptake into peripheral tissues is insulin dependent but the brain, however, utilizes glucose as 
its main energy source independently of insulin. Glucose transports through the blood-brain barrier 
via GLUT1 transporters and into neurons via GLUT3 transporters. (Benarroch, 2014.) Thus, it was 
long thought that insulin had virtually no effect on the brain. However, insulin receptors have been 
found to be expressed in all brain cell types although expression levels differ between regions (Arnold 
et al., 2018). Animal models have shown that insulin receptors are expressed most in olfactory bulb, 
hypothalamus, hippocampus, cortex and thalamus as well as in cerebellum, striatum, midbrain and 
brainstem (Arnold et al., 2018; Ferreira et al., 2018). According to present view, insulin is probably 
not produced in the central nervous system (CNS) but pancreatic insulin is rather transported through 
the blood-brain barrier (Kleinridders et al., 2014; Rhea, Salameh and Banks, 2019). Insulin level is 
significantly lower in cerebrospinal fluid than in blood, although their levels correlate with each other 
– which furthermore supports the pancreas as the source of central nervous system insulin 
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(Kleinridders et al., 2014). To summarize, brain glucose metabolism is not insulin dependent, but it 
appears to be insulin sensitive.  
 
There is evidence suggesting that insulin in the brain influences the metabolism of the whole body 
by acting on hypothalamus: numerous animal studies have found that hypothalamic insulin 
administration reduces food intake. A similar effect is seen in humans as well: insulin administered 
intranasally or intracerebroventricularly acts in an anorexigenic manner, contrary to its peripheral 
effect. (Kullmann et al., 2016.) CNS insulin also suppresses gluconeogenesis and lipolysis (Arnold 
et al., 2018). Regarding cognition, insulin improves overall synaptic plasticity and memory. Insulin 
enhances long term potentiation (LTP) which is the one of the basic mechanisms of memory 
formation. It also affects catecholamine expression and might increase glucose usage in certain areas 
important for memory. (Cholerton, Baker and Craft, 2013.) One of the earliest experimental studies 
regarding CNS insulin and cognition in healthy young adults (N=38, age 18-34 years) found out that 
insulin administered intranasally improved delayed word recall up to 8 weeks after administration 
and even affected mood positively. (Benedict et al., 2004.) 
 
To date, it has been somewhat controversial whether brain IR might be a phenomenon independent 
of peripheral IR. Responsiveness to insulin in brain cells has been found to be impaired in obese 
individuals as well as in individuals with T2D. In addition, age itself increases the risk of brain IR as 
the number of insulin receptors decrease. (Kullmann et al., 2016.) A hypothesis formed on the basis 
of several animal studies claims that dyslipidemia, common in diabetes and obesity, increases blood-
brain barrier permeability which in turn leads to neuroinflammation, IR and neuronal degradation 
(Ferreira et al., 2018). IR has also been proposed to act on the blood-brain barrier permeability, 
meaning that peripheral IR impairs insulin transport into the brain (Heni et al., 2014). While the 
underlying mechanisms between cognitive impairment and brain IR remain uncertain, possible 




1.2  Alzheimer’s disease 
 
 
1.2.1 Epidemiology  
 
Alzheimer’s disease (AD) is the most common type of dementia worldwide (Lane, Hardy and Schott, 
2018) and its prevalence is increasing rapidly as people are living longer than ever. According to the 
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World Health Organization, the amount of people suffering from dementia worldwide will almost 
triple in 35 years from 46 million to 131,5 million (Prince et al., 2015). In Finland, it has been 
estimated that there are approximately 100 000 people living with moderate to severe dementia and 
another 100 000 people with mild dementia today. AD alone constitutes 65-70 % of all dementia 
cases. (Ngandu and Kivipelto, 2018). The second most common type of dementia is vascular 
dementia which often overlaps with AD and shares common risk factors (Kivipelto, Mangialasche 
and Ngandu, 2018). 
 
AD is a devastating progressive disease that gradually leads to death in approximately 8.5 years from 
diagnosis. First, a loss of episodic memory can be seen as well as psychiatric symptoms: depression, 
anxiety, aggression, and behavioral changes. Later on, motor functions deteriorate and eventually 
patients will be totally dependent of their caregivers as their ability to function declines. (Lane, Hardy 
and Schott, 2018.) Mild cognitive impairment, MCI, typically precedes AD diagnosis. MCI is a 
continuum of cognitive decline which does not necessarily lead to dementia, even though the 
incidence is 5 to 30 times higher than in a population with normal cognition. Risk factors for MCI 
conversing into AD are deep white matter lesions and ischemia, diabetes or prediabetes, psychiatric 
symptoms and APOEε4 genotype in addition to other genetic factors. (Campbell et al., 2013.) 
 
Despite decades of research, there is so far neither a cure nor effective drugs to halt AD progression. 
Pathological changes often develop before any notable symptoms. Thus, it is important to be aware 
of modifiable risk factors in order to invest in prevention – preferably even decades before old age 
and possible disease onset.  
 
 
1.2.2 Risk factors 
 
Early-onset AD is a rare (<5% of all cases) hereditary form of AD that occurs in midlife, decades 
earlier than typically. There are three specific autosomal dominant genes known that cause the early-
onset AD. (Bateman et al., 2011.) Regarding the more common sporadic late-onset AD, risk factors 
include both genetic and environmental factors. Different alleles of apolipoprotein E gene (APOE) 
significantly alter the risk of developing AD. APOE is a lipid transport protein expressed in the brain 
as well as in other tissues. APOE gene has three isoforms: APOE2, APOE3, APOE4 and alleles ε2, 
ε3, ε4. (Fan et al., 2019.) APOEε4 genotype is claimed to be the most significant risk factor for 
sporadic AD (Lane, Hardy and Schott, 2018). Being a homozygotic APOEε4 carrier increases the 
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risk of AD to 12-fold compared to non-carriers (Corder et al., 1993). Other genetic risk factors have 
been identified recently but their effect seems to be minimal compared to APOE4 genotypes (Karch 
and Goate, 2015). Apart from APOE genotype, non-modifiable risk factors include age and previous 
head injuries (Ballard et al., 2011). Aging increases incidence of AD exponentially: the incidence of 
AD is 1.6 % in the age group 60-65 years but almost 40 % among people over 90 (Ngandu and 
Kivipelto, 2018). 
 
Barnes and Yaffe estimated that seven, potentially modifiable, risk factors attribute to around half of 
all AD cases. These include diabetes, hypertension, obesity, smoking, depression and low educational 
level or cognitive inactivity. (Barnes and Yaffe, 2011.) In addition, hypercholesterolemia seems to be 
a considerable independent risk factor for AD (Xue-shan et al., 2016.) as well as cerebrovascular 
diseases such as stroke or microvascular lesions (Ngandu and Kivipelto, 2018). IR as a risk factor for 
AD will be discussed later.  
 
Protective factors against AD include cognitive reserve: both high educational level and leisure 
activity can be protective. A diet high in unsaturated fats and antioxidants is favorable as well as 
physical activity. There are controversial results concerning vitamin supplementations or estrogen as 





The hallmark pathological features of AD are extracellular amyloid plaques (also called neurite or 
senile plaques) and intraneuronal neurofibrillary tangles. Amyloid plaques consist of beta-amyloid 
peptides (Aβ40 and Aβ42 isoforms), which are cleavage products of amyloid precursor protein. In 
normal conditions Aβ peptides are soluble monomers but in higher levels they form oligomers and 
eventually fibrils into amyloid plaques. Neurofibrillary tangles contain misfolded and 
hyperphosphorylated tau, a microtubule-associated protein. (Serrano-Pozo et al., 2011.)  
 
The so-called amyloid hypothesis suggests an imbalance between Aβ clearance and production 
activates the development of Alzheimer’s disease. Nevertheless, the number of plaques does not seem 
to correlate with clinical symptoms and beta-amyloid deposits can be seen decades before any 
cognitive decline. Aβ42 oligomers have nevertheless been shown to impair synaptic function and 
structure, stimulate tau hyperphosphorylation and in addition activate inflammation processes. 
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(Selkoe and Hardy, 2016.) Contrary to amyloid plaques, the amount of neurofibrillary tangles 
correlates with clinical symptoms in AD (Serrano-Pozo et al., 2011). However, tau pathology is seen 
also in frontotemporal dementia independently of amyloid accumulation. (Small and Duff, 2008.) 
Braak staging divides neurofibrillary tangle distribution and thus disease progression into six stages 
according to anatomical distribution: I-II transentorhinal, III-IV limbic and V-VI isocortical stages 
(Braak et al., 2006). 
 
Another pathological mechanism in AD is neuroinflammation, which has been suggested to act as a 
mediator between tau and amyloid accumulation. Microglia and astrocytes, immune cells in the brain, 
typically have anti-inflammatory effects in the early stages of AD while neuroprotective pathways 
are working. Nevertheless, overexpressed in AD they begin to secrete inflammatory cytokines which 
results in neuronal degradation. (Kinney et al., 2018.) 
 
Acetylcholine is one of the most important neurotransmitters and cholinergic neurons are widely 
distributed in the brain. Acetylcholine plays a role in many essential neuronal functions, for example 
sleep cycle, memory, and attention. Cholinergic neurons in the basal forebrain are severely damaged 
in AD and the loss of cholinergic neurons correlates with typical symptoms. There are drugs currently 
in use that are targeted to acetylcholine loss, but they only alleviate the symptoms of AD, and do not 
halt disease progression. Cholinesterase inhibitors block the breakdown of the neurotransmitter and 





At present, AD diagnosis can only be determined as “probable” during life since only the postmortem 
neuropathological diagnosis is considered certain. Nevertheless, several diagnostics tools have been 
studied recently and diagnostic criteria might be changing in the future. (Sorbi et al., 2012.) AD is 
rather difficult to diagnose clinically. Careful history of the symptoms must be taken from both the 
patient and the patient’s partner, other family member or caregiver. (Ballard et al., 2011.) MMSE 
(mini mental state examination) is a widely used 30-question screening test for dementia, but it alone 
has low sensitivity and specificity for AD (Arevalo-Rodriguez et al., 2015). CERAD (The 
Consortium to Establish a Registry for Alzheimer's Disease) is a more comprehensive test of 
cognitive function and memory that is used in Finland for screening for memory disorders since its 




In practice, magnetic resonance imaging (MRI) is often used to refine clinical AD diagnosis. It can 
also exclude secondary causes of dementia, such as tumors or inflammatory diseases. (Sorbi et al., 
2012.) Structural MRI reveals brain atrophy that at first in AD is seen to occur in medial temporal 
lobes. Hippocampus, an essential brain region for memory, is a part of the medial temporal lobe and 
its atrophy correlates to memory loss and other cognitive deficits in patients with AD. In addition to 
hippocampal atrophy, other parts of the limbic system are affected, and along disease progression 
also broader cortical regions begin to degenerate. (Chandra et al., 2019.) Traditionally, AD was 
considered a gray matter disease, but this may not be the whole truth, since white matter abnormalities 
can be seen with structural MRI in AD (Caso, Agosta and Filippi, 2016). Diffusion tensor imaging, a 
modality of MRI, detects white matter abnormalities more specifically and will be discussed later.  
 
Positron emission tomography (PET) is rarely used in the clinical diagnosis of AD, but it is a useful 
tool in research. However, PET imaging is used in the diagnosis of memory impairment for working-
age patients when the diagnosis remains unclear after MRI imaging and cerebrospinal fluid samples. 
(Memory Disorders: Current Care Guidelines, 2020.) PET imaging utilizes radioligands that express 
changes in the brain metabolism, circulation, or specific protein aggregations, depending on the used 
ligand, and the results are often combined with structural MRI imaging. Fluorodeoxyglucose (FDG) 
is a glucose analog ligand that in AD shows hypometabolism first in the precuneus and posterior 
cingulate cortex and later in temporo-parietal regions (Valotassiou et al., 2018). Amyloid burden is 
seen to reversely correlate with glucose metabolism (Bao et al., 2017). The most extensively studied 
radioligand regarding AD, 11C-Pittsburgh Compound B (PiB), expresses amyloid deposition. It has a 
very high sensitivity of 96 % for AD but a specificity of only 76 %. Most patients with MCI show 
PiB-retention in a PET scan as well. (Marcus, Mena and Subramaniam, 2014.) Since the amount of 
tau-consisting neurofibrillary tangles seems to correlate with clinical symptoms, tau PET markers 
have been studied but none of them are in clinical use thus far. (Bao et al., 2017; Valotassiou et al., 
2018). 
 
Cerebrospinal fluid (CSF) biomarkers are used in differential diagnostics of AD as well as in research. 
There are three CSF biomarkers in use at present: amyloid-β1-42 , phosphorylated tau (P-tau) and total 
tau (T-tau) (Blennow and Zetterberg, 2013). Typical CSF marker findings in AD are high level of 
total and phosphorylated tau and low level of amyloid-β1-42 which correlate with biopsy findings. 
(Seppälä et al., 2012; Skillbäck et al., 2015). This notion is in line with the idea of amyloid 
aggregation in the brain and a decrease of amyloid-β1-42 has been seen also in people with MCI. T-
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tau on the other hand seems to predict disease progression rapidity, while P-tau correlates with the 




 1.3 Insulin resistance and Alzheimer’s disease 
 
 
IR is a shared feature of T2D, obesity, and AD. The link between IR and AD has been studied with 
great interest using animal models and medical imaging such as PET. (Kullmann et al., 2016; Diehl, 
Mullins and Kapogiannis, 2017.) In a follow-up study of 15 years, IR in midlife was associated with 
a higher amount of brain amyloid accumulation in PET scans in non-demented individuals (Ekblad 
et al., 2018), while opposed PET scan results have also been found (Thambisetty et al., 2013). AD 
has even been proposed to be “type 3 diabetes” because of the notion that AD pathology contributes 
to glucose metabolism disruption (Steen et al., 2005). However, this notion is somewhat 
controversial. Because both IR and AD are gradually developing conditions and share overlapping 
risk factors, their causality may be difficult to establish. Furthermore, the association between 
peripheral and brain IR remains unclear. (Arnold et al., 2018; Ferreira et al., 2018.)  
 
The association between cognitive impairment and IR has been mostly studied in middle-aged and 
elderly populations. Age itself increases risk for both conditions so this connection may be 
coincidental.  (Arnold et al., 2018.) However, in the Framingham Heart Study, a wide cohort study, 
diabetes was associated with impaired memory and attention function (n = 2,126) in young and 
middle-aged people (mean age 40 ± 9 years). Diabetic subjects and subjects with elevated fasting 
blood glucose exhibited both decreased gray matter volumes and fractional anisotropy assessed by 
MRI (n = 1,597). (Weinstein et al., 2015.) 
 
Beta-amyloid and insulin share a common catalytic enzyme IDE, insulin degrading enzyme. It has 
been observed that in a hyperinsulinemic state, Aβ cleavage is reduced, which could be a possible 
link between IR and AD pathology. (Stanley, Macauley and Holtzman, 2016.) In animal studies, 
intracerebroventricular injection of Aβ-oligomers has induced neuronal IR and even peripheral IR. 
Another common feature of diabetes and AD is the formation of advanced glycation end products, 
that show in hyperglycemic conditions – and it might be yet another reason for blood-brain barrier 




Even though it is not known precisely how T2D and AD are linked, diabetes drugs have been studied 
in the treatment of Alzheimer’s disease. Insulin administered subcutaneously mainly acts on 
peripheral tissues, but insulin administered nasally bypasses the blood-brain barrier and reaches the 
CNS trough the cribriform plate. Nasal insulin has been studied in both healthy subjects and MCI or 
AD patients. Even in cognitively healthy subjects, word recall was improved after regular insulin 
administration  which further emphasizes its role in normal cognition. (Yarchoan and Arnold, 2014.) 
A systematic review from 2018 concluded that in seven distinct studies (n = 293), insulin 
administered intranasally improved word and/or story recall in non-APOE4-carrier AD or MCI 




1.4 Diffusion tensor imaging and white matter integrity 
 
 
1.4.1 Principles of diffusion tensor imaging 
 
Diffusion tensor imaging (DTI) is a fairly new modality of MRI that is increasingly used in research 
and clinically. DTI provides information on brain white matter tract anatomy noninvasively in vivo 
based on water diffusion values. Water molecules tend to move randomly due to heat and this 
movement can be observed even in a postmortem brain – which means that it is not solely a 
physiological phenomenon. DTI characterizes diffusion three-dimensionally which allows for a wide 
range of applications. (Mori and Zhang, 2006; Mukherjee et al., 2008.) 
 
Fractional anisotropy (FA) is perhaps the most used value in DTI. It describes symmetry of diffusion 
values. Diffusion in neurons is naturally faster along axons than perpendicularly which allows for 
fiber orientation to be assessed by diffusion values. Thus, FA is considered a generalization of white 
matter integrity. (Bihan et al., 2001; Mori and Zhang, 2006.) FA and mean diffusivity (MD; also 
apparent diffusion coefficient, ADC) are both derived from so-called eigenvectors and their 
eigenvalues λ1, λ2, and λ3. Primary eigenvalue λ1 describes both the magnitude and direction of 
greatest water diffusion along fibers, whereas the other eigenvalues indicate diffusion transversally 
and their mean value is called radial diffusivity (RD). FA value varies from 0 to 1: the maximum 
value 1 indicating that only linear diffusion occurs along primary eigenvector and diffusion is 




Tract-based spatial statistics (TBSS) is a DTI data analysis method developed to improve cross-
subject studies. In order to assess regional changes between subjects, FA data from subjects is first 
registered non-linearly and aligned together, which in TBSS is done by creating a “group mean FA 
skeleton” which ideally represents common tracts among subjects. TBSS reduces the need for 
smoothing and  enables  a more trustworthy voxelwise statistical analysis. (Smith et al., 2006.) 
Tractography, as per its name, is a method of visualizing white matter tracts reconstructed from DTI 
data. Tract orientations are coded in specific colors to make a tractogram demonstrative. Simply put, 
a tractogram, a tractographic image, can be derived from above-mentioned diffusion values when it 
is assumed that one fiber orientation is predominant in a single three-dimensional voxel. These 
presumptions of homogeneity naturally lead to simplifications and false positives as well as false 
negatives. Overall, it is a method that requires a careful user. (Jeurissen et al., 2019.) 
 
 
1.4.2. White matter integrity in Alzheimer’s disease 
 
As stated before, AD affects white matter of the brain in addition to gray matter. According to current 
knowledge, at least some of the changes may be independent of gray matter atrophy. Mechanisms of 
white matter damage in AD remain unclarified and there are different theories of its origin as to 
whether white matter damage is independent of gray matter damage or not. The so-called Wallerian 
degeneration means axonal disruption when separated from cell bodies, thus linking white matter 
damage to gray matter damage. However, there are some studies that suggest white matter damage 
precede grey matter damage in AD. (Sachdev et al., 2013; Caso, Agosta and Filippi, 2016.) According 
to the retrogenesis model, ‘reverse myelogenesis’ is the mechanism of white matter damage. It 
suggests white matter as the primary source of AD pathogenesis, but this theory remains somewhat 
contradictory and may be linked to underlying cerebrovascular conditions. Neuroinflammation has 
also been suggested to be one mechanism of WM damage. (Mayo et al., 2017.)  
 
White matter hyperintensity seen in conventional MRI indicates demyelination and axonal loss along 
white matter tracts in AD. DTI nonetheless provides more specific information on exact WM tracts 
affected by AD. Tractography studies have shown wide white matter damage in major limbic tracts 
including cingulum and fornix and corticocortical association tracts such as corpus callosum in AD 




In a cross-sectional study from 2011, DTI was performed on 23 AD patients, 15 patients with 
amnestic mild cognitive impairment (aMCI) and 15 control subjects. Researchers used two most 
common DTI values MD and FA to estimate white matter microstructure impairment. In addition, 
gray matter morphometry was used to investigate whether WM and GM atrophy correlated. AD 
patients exhibited increase in MD widely across various WM tracts: e.g., cortico-cortical, 
corticospinal, interhemispheric, and limbic tracts while FA decrease was seen only in smaller tracts.  
There was an increase in axial diffusivity in aMCI patients, mostly in tracts projecting to the frontal 
cortex but no significant changes in other values were found. In AD patients some correlations 
between WM impairment and regional gray matter atrophy were found but rather inconsistently. 
(Agosta et al., 2011.) 
 
In a more recent longitudinal study by Mayo et al. (2017), DTI data obtained from 34 AD patients 
and 33 controls were compared at baseline and at one year. In TBSS analysis, AD patients showed 
increased MD and decreased FA widely in white matter tracts in the medial temporal lobe compared 
to control subjects, and these changes were greater at one year. Also, healthy controls showed signs 
of white matter microstructure impairment due to aging but less extensively than AD patients, and in 
controls hippocampal cingulum was spared unlike in AD. These findings appeared to be in line with 








This literature review was done in Turku PET center as a part of research project CIRI (Cognition, 
Insulin Resistance, and Inflammation), a neuroimaging study on 60 elderly volunteers which was 
conducted to evaluate the associations between midlife IR and late-life cerebral changes related to 
cognitive decline. The study participants underwent magnetic resonance imaging including DTI 
imaging, and positron emission tomography with two different radiotracers to assess brain amyloid 
burden and neuroinflammation. In addition, a comprehensive cognitive test battery was performed to 




Database search was performed on the 30th of November in 2019 in PubMed database. Following 
search query was used: (DTI* OR “diffusion tensor imaging” OR tractograph*) AND (insulin 
resistance* OR hyperglycemia* OR diabetes* OR metabolic syndrome* OR MetS*) AND (cogniti* 
OR MCI* OR AD* OR Alzheimer's disease* OR dementia*). Only articles written in English and 
original research articles were included.  
 
For the literature review, there were following criteria for included articles: 1) study includes an 
insulin resistant (not only a T2D group) and control group 2) white matter changes were assessed 
using DTI 3) cognitive performance was measured 4) subjects had no dementia. 149 articles were 
found using the before-mentioned search query. Only three of those met the inclusion criteria and 




3 Review of the literature 
 
 
The purpose of this literature review is to evaluate the association between IR and white matter 
integrity according to current knowledge. In addition, a possible link between AD and the action of 
IR on brain white matter is considered. 
 
While IR as a risk factor for white matter abnormalities is not established, more is known about the 
effects of diabetes on white matter tracts. In a study by Reijmer et al. (2013), a group of elderly (mean 
age 71 ± 5 years) T2D patients demonstrated abnormalities widely in white matter tracts using 
tractography. These impairments were associated with poorer cognitive function in the diabetic 
group, although the same association was not seen in control group. In the T2D group, MD was 
significantly increased in all major white tracts studied (the superior longitudinal fasciculus, the 
uncinate fasciculus, the inferior longitudinal fasciculus, and the genu and splenium of the corpus 
callosum).  
 
Other studies have found similar results regarding the effects of diabetes on white matter studying 
middle-aged patients (Tan et al., 2016) and they might be associated with microvascular 
complications of diabetes (Zhuo et al., 2019). Xiong et al. (2016) suggest that a change in DTI values 
might indicate a cognitive decline in patients with T2D. In their study, diabetic subjects were divided 
13 
 
into those with MCI and without. TBSS analysis revealed that those with MCI exhibited greater MD 
and FA changes than those without compared to healthy controls. However, only cross-sectional 
results were reported. (Xiong et al., 2016.)  
 
A recent study found out that heightened blood glucose levels, even below diagnostic cutoff values 
for diabetes, in healthy young adults (mean age 28.8 years, n = 1206) were associated with poorer 
white matter integrity. Glycated hemoglobin HbA1c (range 4.1 - 6.3 %) was found to have a negative 
correlation with both cognitive performance and FA value. (Repple et al., 2019)  
 
A few studies have been focusing specifically on IR and white matter abnormalities and these are the 
focus of this review. The first one by Ryu et al. (2014) included 127 healthy middle-aged and older 
participants that were divided into two subgroups according to their IR status assessed by HOMA-
IR. DTI was performed on all subjects and analyzed using TBSS. High HOMA-IR group (n = 27) 
showed lower axial diffusivity (DA) values broadly in white matter regions including frontal, 
temporal and parietal white matter, corpus callosum and corona radiata (see Fig. 1). FA changes were 
not as significant but overlapping of both FA and DA decrease was seen in corpus callosum and some 
connection fibers. APOE status did not have an effect on these findings. White matter integrity loss 
was associated with IR independently of aging and usage of antihypertensive medication in this study. 
Cognitive function was assessed by MMSE and there was virtually no difference between the study 
groups.  
 
More recently, Liang et al. (2019) published a TBSS study with somewhat similar results. Sixty 
middle-aged participants were divided into prediabetic and control groups. Their IR status was 
assessed by OGTT. The APOE status of the participants was not identified. In the prediabetic group 
FA was lower in right corpus callosum and left and right superior longitudinal fasciculus compared 
to the control group. No other differences were observed between groups in other DTI indices: MD, 
RD, and DA. In addition to MMSE, other neuropsychological tests, MoCA, SAS and SDS, were used. 
FA value correlated weakly with neuropsychological test results, but these findings were not 
statistically significant.  
 
The Maastricht Study is a large cohort study focused on T2D and its comorbidities. Vergoossen et al. 
(2019) published a tractography study (N=2219) about white matter connectivity in both T2D and 
prediabetes. Whole brain tractography was performed on three subgroups: subjects with normal 
glucose metabolism, prediabetes, and T2D. Potential confounding variables, such as sex, education 
14 
 
level and cardiovascular risk factors were considered, and analyses adjusted for them. Overall node 
degree, indicating WM area connectivity, was found to be significantly lower in both prediabetic and 
diabetic groups compared to control group. This decrease of node degree equaled to 2.3 and 10.4 
years of aging, respectively, compared to controls with normal glucose metabolism. Furthermore, 
even hyperglycemia continuously measured by HbA1c and fasting blood glucose was inversely 
correlated to node degree.  
 
In prediabetic subjects WM tract volume was diminished only in interhemispheric connections while 
in T2D both intra- and interhemispheric tracts were affected. Indices describing network organization, 
so called graph measures, were affected in prediabetes. Local connectivity assessed by clustering 
coefficient was lower in addition to lower local efficiency. These changes were not observed in 
diabetic group, but instead T2D associated with higher communicability which was hypothesized to 
be due to adaptation to white matter lesions. MMSE results were marginally lower in both prediabetic 
and diabetic groups and in this large cohort the difference was found to be statistically significant. 
(Vergoossen et al., 2019.) 
 
 
Table 1. A comparison of demographic data and results between DTI studies. 
OGTT= oral glucose tolerance test, TBSS= tract based spatial statistics, FA= fractional anisotropy, DA= 
axial diffusivity, CC=corpus callosum, HOMA-IR=homeostasis model assessment of insulin resistance. 














OGTT 55.0 ± 6.7 / 
52.8 ± 7.5 
 
29.4 ± 0.7 / 
29.7 ± 0.5 
(p 0.14) 
TBSS decreased FA in 
prediabetic group in 
right part of CC and 
left superior 
longitudinal fasciculus 








62.5 ± 11.5 /  
62.1 ± 10.3  
28.6 ± 1.5 / 
28.6 ± 1.5  
(p 0.89) 
TBSS decreased FA in CC, 
parts of corona radiata; 
decreased DA in WM 
of frontal, parietal and 
temporal lobes 
Vergoossen 







OGTT 62.5 ± 7.6, 
61.2 ± 7.5 /  
57.6 ± 8.1 
 
28.7 ± 1.3, 
28.9 ± 1.1 / 




both prediabetes and 
T2D groups exhibit 
lower node degree and 









In this literature review, IR and its effect on brain white matter integrity was investigated. Three 
publications from recent years addressing the topic were included. In all the included studies DTI 
showed changes in diffusion values and connectivity and thus white matter microstructure in subjects 
with IR. Cognitive performance assessed by MMSE showed minimal impairment in IR only in one 
study. MMSE alone in non-demented individuals is not a sensitive tool to assess cognitive 
performance (Arevalo-Rodriguez et al., 2015) and in order to study the relationship between IR, white 
matter impairment and cognitive performance, more extensive neuropsychological tests are needed 
in future studies.  
 
The two TBSS studies had both relatively small study populations and were cross-sectional (Ryu et 
al., 2014; Liang et al., 2019) while the study by Veergoossen et al. included a significantly larger 
study population. The study populations of all studies were roughly of same age (mean ages 52.8 – 
62.5 years) but from different cultural backgrounds and supposedly different educational systems and 
different levels of education.  
 
In the Maastricht study the differences in MMSE scores between diabetic and non-diabetic groups 
were found to be statistically significant. However, education levels varied substantially between the 
groups: the diabetic and prediabetic groups had a lower education level in average compared to the 
non-diabetic group but this was taken into account in the analyses. (Vergoossen et al., 2019.) High 
educational level is a known protective factor against cognitive decline and AD (Ballard et al., 2011). 
In diabetic and prediabetic groups, there were more metabolic risk factors present: higher body mass 
index, higher prevalence of hypertension and lipid-modifying-medication, which were taken into 
account – contrary to the other studies here (Vergoossen et al., 2019).  
 
Regarding the methods to assess IR, Ryu et al. used HOMA-IR assessment while the others used a 
simpler method, OGTT. High HOMA-IR group in their study did not equal prediabetic, because both 
groups even had some participants diagnosed with T2D and users of oral diabetes medication (Ryu 




Furthermore, there were two distinct DTI analysis methods used in these studies, tractography and 
TBSS, which makes it difficult to compare white matter impairment in any specific brain regions 
between the studies. In addition, TBSS studies both exhibited changes in diffusion values, but not in 
the same parameters. This demonstrates the need for further studies. While AD has been shown to 
affect brain white matter integrity in various regions, it is not yet possible to draw conclusions that 
these changes are mediated by IR as there is not enough evidence to support this hypothesis.  
 
In conclusion, the results of this literature review suggest that IR in middle-aged subjects might 
contribute to brain white matter integrity loss. IR, prediabetes, and type 1 and 2 diabetes have 
consistently been linked to cognitive decline, but the underlying pathophysiological mechanisms 
causing cognitive decline are not yet clear. Based on the existing literature, white matter integrity loss 
seems to play a part in cognitive decline in prediabetic individuals. Nevertheless, follow-up studies 
need to be conducted in the future to establish this connection and a possible further connection to 
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